HIV entry inhibitors in clinical development

Current Opinion in Pharmacology

Volumn 2, Issue 5, 2002, Pages 523-528

  O'Hara, Bryan M ^a   Olson, William C ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; AMD 3645; ANTIVIRUS AGENT; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; PRO 140; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; ERADICATION THERAPY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; PARESTHESIA; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TACHYCARDIA; VIRUS ADSORPTION; VIRUS REPLICATION;

EID: 0036790563     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00196-0     Document Type: Review

References (64)

1. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B: The global impact of HIV/AIDS. Nature 2001, 410:968-973.
2. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2000, 283:381-390.
3. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
4. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
5. Wise A, Gearing K, Rees S: Target validation of G-protein coupled receptors. Drug Discov Today 2002, 7:235-246.
6. Trkola A, Pomales AP, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2. J Virol 1995, 69:6609-6617.
7. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DNH, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ: Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000, 182:326-329.
8. Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B et al.: Recombinant CD4-IgG2 in HIV-1 infected children: Phase I/II study. J Infect Dis 2000, 182:1774-1779.
9. O'Hara BM, Olson WC, Israel RJ, Barish M, Maddon PJ, Lowy I, Jacobson JM: Salvage therapy of HIV-1 infection with PRO 542, a novel inhibitor of viral attachment and entry. Abstract LB-2 of the 15th International Conference on Antiviral Research, 2002 March 17-21, Prague, The Czech Republic.
10. Lin PF, Guo K, Fridell R, Ho H.-T., Yamanaka G, Colonno R: Identification and characterization of a novel inhibitor of HIV-1 entry - II: mechanism of action. Abstract 10 of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
11. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
12. Clapham PR, McKnight A: HIV-1 receptors and cell tropism. Br Med Bull 2002, 58:43-59.
13. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H: Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 1999, 180:1106-1115.
14. Li S, Juarez J, Alali M, Dwyer D, Collman RG, Cunningham A, Naif HM: Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol 1999, 73:9741-9755.
15. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort ALIVE Study. Science 1996, 273:1856-1862.
16. Huang Y, Paxton W, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240.
17. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999, 96:5698-5703.
18. Dorn CP, Finke PE, Oates B, Budhu RJ, Mills SG, MacCoss M, Malkowitz L, Springer MS, Daugherty BL, Gould SL et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001, 11:259-264.
19. Finke PE, Meurer LC, Oates B, Mills SG, MacCoss M, Malkowitz L, Springer MS, Daugherty BL, Gould SL, DeMartino JA et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001, 11:265-270.
20. Finke PE, Oates B, Mills SG, MacCoss M, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Carella A, Carver G et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl) amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl) amino)piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001, 11:2475-2479.
21. Kim D, Wang L, Caldwell CG, Chen P, Finke PE, Oates B, MacCoss M, Mills SG, Malkowitz L, Gould SL et al.: Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg Med Chem Lett 2001, 11:3103-3106.
22. Kim D, Wang L, Caldwell CG, Chen P, Finke PE, Oates B, MacCoss M, Mills SG, Malkowitz L, Gould SL et al.: Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg Med Chem Lett 2001, 11:3099-3102.
23. Lynch CL, Gentry AL, Hale JJ, Mills SG, MacCoss M, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ et al.: CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. Bioorg Med Chem Lett 2002, 12:677-679.
24. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM: Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyiminol) bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 2001, 44:3339-3342.
25. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:12718-12723.
26. Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3- pyridinyl)carbonyl]- 4-methyl-4-[3(S)- methyl-4- [1(S)-[4-(trifluoromethyl) phenyl]ethyl]-1-piperazi nyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem 2001, 44:3343-3346.
27. Willoughby CA, Berk SC, Rosauer KG, Degrado S, Chapman KT, Gould SL, Springer MS, Malkowitz L, Schleif WA, Hazuda D et al.: Combinatorial synthesis of CCR5 antagonists. Bioorg Med Chem Lett 2001, 11:3137-3141.
28. Olson W, Dragic T, O'Hara B, Nagashima K, Tsamis F, Westby M, Cammack N: Identification of CCR5 co-receptor inhibitors that potently and selectively block HIV-1 replication. Abstract 402-T of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
29. Reyes G: Development of CCR5 antagonists as a new class of anti-HIV therapeutic. Abstract L11 of the 8th Conference on Retroviruses and Opportunistic Infections, 2001 February 4-8, Chicago, IL.
30. Reynes J, Rouzier R, Kanouni T, Baillat V, Baroudy B, Keung A, Hogan C, Markowitz M, Laughlin M: SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. Abstract 1 of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
31. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo F, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000, 97:5639-5644.
32. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, Issafras H, Stangassinger M, Vassart G, Marullo S, Schlndorff D et al.: Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 2002, 13:723-737.
33. Hill CM, Kwon D, Jones M, Davis CB, Marmon S, Daugherty BL, DeMartino JA, Springer MS, Unutmaz D, Littman DR: The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 1998, 248:357-371.
34. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999, 73:4145-4155.
35. Osbourn JK, Earnshaw JC, Johnson KS, Parmentier M, Timmermans V, McCafferty J: Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol 1998, 16:778-781.
36. Vila-Coro AJ, Mellado M, Martin DA, Lucas P, del Real G, Martinez A, Rodriguez-Frade JM: HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 2000, 97:3388-3393.
37. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M et al.: Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp 120 binding and a single domain for chemokine binding. J Exp Med 1997, 186:1373-1381.
38. Wu L, Paxton W, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681-1691.
39. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001, 75:579-588.
40. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP et al.: Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998, 72:279-285.
41. Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T: Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci USA 2000, 97:5762-5767.
42. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H: Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999, 96:667-676.
43. Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T: Mapping the determinants of the CCR5 amino-terminal sulfopeptide Interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 2001, 75:5541-5549.
44. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4:72-77.
45. Hendrix C, Collier A, Lederman M, Pollard R, Brown S, Glesby M, Flexner C, Bridger G, Badel K, MacFarland R et al.: AMD-3100 CXCR4 receptor blocker fails to reduce HIV viral load by ≥ 1 log following 10-day continuous infusion. Abstract 391-T of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
46. Schols D, Claes S, De Clercq E, Hendrix C, Bridger G, Calandra G, Henson GW, Fransen S, Huang W, Whitcomb JM, Petropoulos CJ: AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. Abstract 2 of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
47. Hatse S, Princen K, Bridger G, Skerlj R, Henson G, De Clercq E, Schols D: A specific CXCR4 antagonist with potent anti-HIV activity. Abstract 5 of the 15th International Conference on Antiviral Research, 2002 March 17-21, Prague, Czech Republic.
48. Rimsky LT, Shugars DC, Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72:986-993.
49. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307
50. Lalezari J, DeJesus E, Northfelt D, Richmond G, Delehanty J, DeMasi R, Salgo M: A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naive patients infected with HIV-1. Abstract 418-W of the 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, Seattle, WA.
51. Eron J, Merigan T, Kilby M, Yangco B, Gleavy J, Rusnak P, Dimassimo B, Smith R, Baker B, Duff F et al.: A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. Abstract 14 of the 8th Conference on Retroviruses and Opportunistic Infections, 2001 February 4-8, Chicago, IL.
52. Chan DC, Chutkowski CT, Kim PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998, 95:15613-15617.
53. Root MJ, Kay MS, Kim PS: Protein design of an HIV-1 entry inhibitor. Science 2001, 291:884-888.
54. Nagashima KA, Thompson DAD, Rosenfield SI, Maddon PJ, Dragic T, Olson WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001, 183:1121-1125.
55. Tremblay C, Kollman C, Giguel F, Chou TC, Hirsch MS: Strong in vitro synergy observed between the fusion inhibitor T-20 and a CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000, 25:99-102.
56. Olson W, Nagashima K, Rosenfield S, Maddon P: Comparative and combinatorial analysis of the HIV-1 entry inhibitors PRO 542, T-20 and PRO 140. Abstract WcOrA533 of the 13th International AIDS Conference, 2000 July 12, Durban, South Africa.
57. Baribaud F, Pohlmann S, Doms RW: The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission. Virology 2001, 286:1-6.
58. Steinman RM: DC-SIGN: a guide to some mysteries of dendritic cells. Cell 2000, 100:491-494.
59. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Richman D et al.: Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000, 181:354-357.
60. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, Kerkering TM, Ferreira-Gonzalez A, Szakal AK, Tew JG, Burton GF: Persistence of infectious HIV on follicular dendritic cells. J Immunol 2001, 166:690-696.
61. Stahl-Hennig C, Steinman RM, Tenner-Racz K, Pope M, Stolte N, Matz-Rensing K, Grobschupff G, Raschdorff B, Hunsmann G, Racz P: Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999, 285:1261-1265.
62. + T cells. Science 1999, 286:1353-1357.
63. Henry K, Lalezari J, O'Hearn M, Trottier B, Montaner J, Piliero P, Walmsley S, Chung J, Fang L, Delehanty J, Salgo M: Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil (TORO 1). Abstract LbOr19B of the 14th International AIDS Conference, 2002 July 7-12, Barcelona, Spain.
64. Clotet B, Lazzarin A, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Chung J, Fang L, Delehanty J, M Salgo M: Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia (TORO 2). Abstract LbOr19A of the 14th International AIDS Conference, 2002 July 7-12, Barcelona, Spain.